# Insulin Glargine During and After the Period of Fasting in Ramadan

> **NCT00258804** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 450 (—)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin glargine

## Key facts

- **NCT ID:** NCT00258804
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 450 (—)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258804, "Insulin Glargine During and After the Period of Fasting in Ramadan". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00258804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*